For patients with triple negative breast cancer, the aggressive choice of surgery should be followed by complementary intravenous chemotherapy. Because patients are prone to recurrence or metastasis 1-3 years after surgery, the common regimen is mainly the choice of docetaxel, combined with cisplatin or the application of lopressor. It is also important to monitor changes in blood and liver and kidney function indicators during treatment, as many are prone to secondary myelosuppression, and patients may also experience significant weakness, decreased appetite, nausea, and vomiting. Along with the medication, liver-protective, kidney-protective, and gastrointestinal mucosa-protective drugs are routinely given, as well as leukocyte-lifting drugs and subcutaneous injections of recombinant human granulocyte colony-stimulating factor when necessary. During the treatment period, the patient is advised to increase the nutrition of the diet, eat more light food, stay away from fried food and greasy food, and do physical exercise appropriately.